Clinical studies in CCM have shown reduced levels of insulin in these individuals, mainly due to an increase in adiponectin levels, simultaneous to a decrease in leptin levels, among other alterations that promote a change in the function of the stimulus-secretion pathway [32, 33, 34]. The gene discussed is LEP; the disease is cerebral cavernous malformation.